• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 3. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

Introduction to 1-(3-methylphenyl)cyclobutan-1-amine hydrochloride (CAS No. 1416438-03-3)

1-(3-methylphenyl)cyclobutan-1-amine hydrochloride, identified by its Chemical Abstracts Service (CAS) number 1416438-03-3, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical research and chemical synthesis. This compound belongs to the class of amine derivatives, featuring a cyclobutane ring substituted with a phenyl group at the 3-position and an amine functional group at the 1-position, all further modified by hydrochloride salt form for enhanced solubility and stability.

The structural uniqueness of 1-(3-methylphenyl)cyclobutan-1-amine hydrochloride lies in its fused cyclobutane and aromatic ring system, which creates a rigid yet flexible molecular framework. This architecture is particularly intriguing for medicinal chemists due to its potential to interact with biological targets in novel ways. The presence of the methyl substituent on the phenyl ring introduces steric and electronic effects that can modulate binding affinities and metabolic stability, making it a valuable scaffold for drug discovery.

In recent years, there has been growing interest in developing small molecules that can modulate neurotransmitter systems, particularly those involving dopamine and serotonin receptors. The 1-(3-methylphenyl)cyclobutan-1-amine hydrochloride structure bears resemblance to known pharmacophores found in atypical antipsychotics and antidepressants. Preliminary computational studies suggest that this compound may exhibit binding properties relevant to serotonin 5-HT2A and dopamine D2 receptors, which are critical targets in the treatment of neuropsychiatric disorders.

One of the most compelling aspects of 1-(3-methylphenyl)cyclobutan-1-amine hydrochloride is its potential as a building block for more complex drug candidates. Its cyclobutane core provides a stable platform that can be further functionalized to introduce additional pharmacological properties. For instance, researchers have explored derivatives of this compound that incorporate polar or charged groups to enhance receptor selectivity or improve pharmacokinetic profiles. Such modifications are essential for translating early-stage hits into viable therapeutic agents.

The synthesis of 1-(3-methylphenyl)cyclobutan-1-amine hydrochloride presents both challenges and opportunities for synthetic chemists. The cycloaddition reactions between cyclopropyl halides and aziridines are commonly employed strategies to construct the cyclobutane ring system. Additionally, the introduction of the 3-methylphenyl group requires careful consideration of reaction conditions to avoid unwanted side products. Advances in catalytic methods, such as transition-metal-catalyzed cross-coupling reactions, have streamlined the synthesis of complex aromatic amine derivatives, making compounds like 1-(3-methylphenyl)cyclobutan-1-amine hydrochloride more accessible than ever before.

From a pharmacological perspective, the amine functionality in 1-(3-methylphenyl)cyclobutan-1-amine hydrochloride offers multiple possibilities for interaction with biological targets. The primary amine can be further modified into secondary or tertiary amines through alkylation or acylation reactions, which can significantly alter the compound's pharmacological activity. Moreover, the hydrochloride salt form enhances water solubility, facilitating its use in in vitro and in vivo studies. This solubility advantage is particularly important for drug candidates intended for oral administration or intravenous delivery.

Recent preclinical studies have begun to explore the potential therapeutic applications of 1-(3-methylphenyl)cyclobutan-1-amine hydrochloride. In cell-based assays, this compound has demonstrated modest activity against certain serotonin receptor subtypes, suggesting its utility as an intermediate in developing novel serotonin receptor modulators. Additionally, its structural features may contribute to neuroprotective effects by interacting with mitochondrial enzymes or reducing oxidative stress—a mechanism relevant to neurodegenerative diseases such as Alzheimer's and Parkinson's.

The role of computational chemistry in optimizing 1-(3-methylphenyl)cyclobutan-1-amine hydrochloride cannot be overstated. Molecular modeling techniques allow researchers to predict binding affinities, identify potential metabolic pathways, and design analogs with improved properties. By leveraging machine learning algorithms trained on large datasets of known drug candidates, scientists can accelerate the discovery process and prioritize compounds for experimental validation. This interdisciplinary approach has become indispensable in modern drug development pipelines.

The future prospects for 1-(3-methylphenyl)cyclobutan-1-amine hydrochloride are promising, given its structural versatility and potential therapeutic relevance. As pharmaceutical research continues to evolve, new synthetic methodologies and computational tools will further enhance our ability to harness this compound's full potential. Collaborative efforts between synthetic chemists, medicinal chemists, and biologists will be crucial in translating laboratory findings into clinical applications that benefit patients worldwide.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)